Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 19;20(3):3549–3564. doi: 10.3390/molecules20033549

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Activity of silibinin against methylglyoxal-induced glycation, revealed by the immunostaining of CML. Immunostaining of CML in untreated batch (A), treated with AG (B), treated with SMFE (C), treated with MG (D), treated with MG + AG (E) and treated with MG + SMFE (F). (G) Staining intensity on batches treated with active ingredients on CML immunostaining. The average staining intensity values were calculated using Image J software. Data are mean ± standard deviation. ^§ p < 0.01 compared with the vehicle-treated group, ^# p < 0.05 compared with the MG treated group, ^## p < 0.01 compared with the MG treated group (n = 3).

Activity of silibinin against methylglyoxal-induced glycation, revealed by the immunostaining of CML. Immunostaining of CML in untreated batch (A), treated with AG (B), treated with SMFE (C), treated with MG (D), treated with MG + AG (E) and treated with MG + SMFE (F). (G) Staining intensity on batches treated with active ingredients on CML immunostaining. The average staining intensity values were calculated using Image J software. Data are mean ± standard deviation. ^§ p < 0.01 compared with the vehicle-treated group, ^# p < 0.05 compared with the MG treated group, ^## p < 0.01 compared with the MG treated group (n = 3).